Skip to Main Content
Diseases are natural phenomena and consequently are amenable to mathematical and computational description. Clinically driven complex multi-scale disease models are capable of producing realistic spatio-temporal and patient-specific simulations of several clinical interventions. Clinical data-processing procedures and computer technologies play an important role in this context. Following clinical adaptation and validation within the framework of clinicogenomic trials, models are expected to advance the prospect of individualized treatment optimization, this being the long term goal of the emergent scientific, technological and medical discipline of in silico medicine. In silico oncology has proven to be inter alia an excellent didactic, research and clinical paradigm of this new discipline, since cancer is strongly manifested at all scales of biocomplexity.
Treatment optimization is to be achieved through experimentation in silico i.e. on the computer. Moreover, provision of improved insight into disease dynamics and optimization of clinical trial design and interpretation constitute short- and mid-term goals of this new domain. The IEEE-EMBS technically co-sponsored 6th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation (6th IARWISOCI) (www.6th-iarwisoci.iccs.ntua.gr).being also the CHIC project workshop (http://chic-vph.eu/), proved an excellent opportunity for contributing to the shaping of the discipline. The presented papers deal with modeling of tumor dynamics and response to treatment from the biochemical to the macroscopic level and from basic science to clinics via information technology and legal and ethical handling. They have been contributed by top international researchers and research groups. This year's workshop was dedicated to Aristotle and special focus was put on the collection, processing, exploitation and legal and ethical aspects of the clinical multiscale data which represent the Aristotelian observable reality for the advancement of in silico oncology. A one hour session of the workshop was held on the very site of Aristotle's Peripatetic School. The workshop took place in Athens, Greece on 3–4 November 2014.
In silico oncology could be formally defined as being” … a complex and multiscale combination of sciences, technologies and clinical medicine intending to simulate malignant tumor growth and tumor and normal tissue response to therapeutic modalities at all biomedically meaningful spatio-temporal scales”. Its long term goal is to quantitatively understand cancer and related phenomena and optimize therapeutic interventions by performing in silico experiments using clinical, imaging, histopathological, molecular and pharmacogenomic data from individual patients. In order to achieve such an ambitious goal translation of cancer models and oncosimulators or more generally clinical simulators into the clinical trials arena is a sine qua non condition.
The Organizing Committee of the workshop consisted of the following persons
G. Stamatakos, PhD, ICCS–National Technical University of Athens (GR), General Chair
N. Graf, MD, University of Saarland (DE)
M.Akay, PhD, University of Houston (US)
D.Dionysiou, PhD, ICCS–National Technical University of Athens (GR)
K.Marias, PhD, Foundation for Research and Technology Hellas (GR)
R.Radhakrishnan, PhD, University of Pennsylvania (US) N.Uzunoglu, PhD, ICCS–National Technical University of Athens (GR)
The workshop was funded by the European Commission through the transatlantic CHIC project (FP7- Grant Agreement No 600841).
Back to Top